Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey

Bibliography

• Rucker RB, O'Dell BL. Connective tissue amine oxidase I. Purification of bovine aorta amine oxidase and its comparison with plasma amine oxidase. Biochim Biophys Acta Enzymol 1971;235:32-43
   Google Scholar
• Boomsma F. Semicarbazide-sensitive amine oxidases: widespread occurrence and many names and faces. Neurobiol (Bp) 2000;8:1-16
   Google Scholar
• Tipton KF, O'sullivan MI, Davey GP, O'sullivan J. It can be a complicated life being an enzyme. Biochem Soc Trans 2003;31:711-15
   Google Scholar
• Jalkanen S, Salmi M. Cell surface monoamine oxidases: enzymes in search of a function. EMBO J 2001;20:3893-901
   PubMed Web of Science ®Google Scholar
• Holt A, Alton G, Scaman CH, Identification of the quinone cofactor in mammalian semicarbazide-sensitive amine oxidase. Biochemistry 1998;37:4946-57
   PubMedGoogle Scholar
• Williams NK, Klinman JP. Whence topa? Models for the biogenesis of topa quinone in copper amine oxidases. J Mol Catal B Enzym 2000;8:95-101
   Google Scholar
• Mure M, Mills SA, Klinman JP. Catalytic mechanism of the topa quinone containing copper amine oxidases. Biochemistry 2002;41:9269-78
   PubMed Web of Science ®Google Scholar
• Brazeau BJ, Johnson BJ, Wilmot CM. Copper-containing amine oxidases. Biogenesis and catalysis; a structural perspective. Arch Biochem Biophys 2004;428:22-31
   PubMed Web of Science ®Google Scholar
• Gubisne-Haberle D, Hill W, Kazachkov M, Protein cross-linkage induced by formaldehyde derived from semicarbazide-sensitive amine oxidase-mediated deamination of methylamine. J Pharmacol Exp Ther 2004;310:1125-32
   PubMed Web of Science ®Google Scholar
• Matyus P, Dajka-Halasz B, Foldi A, Semicarbazide-sensitive amine oxidase: current status and perspectives. Curr Med Chem 2004;11:1285-98
   Web of Science ®Google Scholar
• Dunkel P, Gelain A, Barlocco D, Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target. Curr Med Chem 2008;15(9):1827-39
   Google Scholar
• Boomsma F, Bhaggoe UM, van der Houwen AMB, van den Meiracker AH. Plasma semicarbazide-sensitive amine oxidase in human (patho)physiology. Biochim Biophys Acta Proteins Proteomics 2003;1647:48-54
   PubMed Web of Science ®Google Scholar
• Schwelberger HG. The origin of mammalian plasma amine oxidases. J Neural Transm 2007;114:757-62
   PubMed Web of Science ®Google Scholar
• Schwelberger HG. Structural organization of mammalian copper-containing amine oxidase genes. Inflamm Res 2010;59(Suppl 2):S223-5
   Google Scholar
• Chassande O, Renard S, Barbry P, The human gene for diamine oxidase, an amiloride binding protein. Molecular cloning, sequencing, and characterization of the promoter. J Biol Chem 1994;269:14484-9
   PubMed Web of Science ®Google Scholar
• Imamura Y, Kubota R, Wang Y, Human retina-specific amine oxidase (RAO): cDNA cloning, tissue expression, and chromosomal mapping. Genomics 1997;40:277-83
   PubMed Web of Science ®Google Scholar
• Imamura Y, Noda S, Mashima Y, Human retina-specific amine oxidase: genomic structure of the gene (AOC2), alternatively spliced variant, and mRNA expression in retina. Genomics 1998;51:293-8
   PubMed Web of Science ®Google Scholar
• Zhang Q, Mashima Y, Noda S, Characterization of AOC2 gene encoding a copper-binding amine oxidase expressed specifically in retina. Gene 2003;318:45-53
   Google Scholar
• Zhang X, McIntire WS. Cloning and sequencing of a copper-containing, topa quinone-containing monoamine oxidase from human placenta. Gene 1996;179:279-86
   PubMed Web of Science ®Google Scholar
• Smith DJ, Salmi M, Bono P, Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J Exp Med 1998;188:17-27
   PubMed Web of Science ®Google Scholar
• Jakobsson E, Nilsson J, Ogg D, Kleywegt GJ. Structure of human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1. Acta Crystallogr D 2005;61:1550-62
   PubMed Web of Science ®Google Scholar
• Airenne TT, Nymalm Y, Kidron H, Crystal structure of the human vascular adhesion protein-1: Unique structural features with functional implications. Protein Sci 2005;14:1964-74
   PubMed Web of Science ®Google Scholar
• Jakobsson E, Nilsson J, Kallstrom U, Crystallization of a truncated soluble human semicarbazide sensitive amine oxidase. Acta Crystallogr F 2005;61:274-8
   Google Scholar
• Ernberg K, McGrath AP, Peat TS, A new crystal form of human vascular adhesion protein 1. Acta Crystallogr F 2010;66:1572-8
   Google Scholar
• Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med 1993;178:2255-60
   PubMed Web of Science ®Google Scholar
• Jaakkola K, Nikula T, Holopainen R, In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am J Pathol 2000;157:463-71
   PubMed Web of Science ®Google Scholar
• Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 1992;257:1407-9
   PubMed Web of Science ®Google Scholar
• Salmi M, Jalkanen S. VAP-1: an adhesin and an enzyme. Trends Immunol 2001;22:211-16
   PubMed Web of Science ®Google Scholar
• Jalkanen S, Salmi M. A novel endothelial cell molecule mediating lymphocyte binding in man. WO25582; 1993
   Google Scholar
• Jalkanen S, Salmi M. Vascular adhesion protein-1 (VAP-1) and VAP-1 specific antibodies. US5580780; 1996
   Google Scholar
• Biotie Therapies. Vascular adhesion protein VAP-1 having amine oxidase activity. WO53049; 1998
   Google Scholar
• Yraola F, Albericio F, Royo M. Inhibition of VAP1: quickly gaining ground as an anti-inflammatory therapy. ChemMedChem 2007;2:173-4
   PubMed Web of Science ®Google Scholar
• McDonald IA, Foot J, Yin P, Semicarbazide sensitive amine oxidase and vascular adhesion protein-1: one protein being validated as a therapeutic target for inflammatory diseases. Annu Rep Med Chem 2007;42:229-43
   Google Scholar
• Salmi M, Yegutkin GG, Lehvonen R, A cell surface amine oxidase directly controls lymphocyte migration. Immunity 2001;14:265-76
   PubMed Web of Science ®Google Scholar
• Koskinen K, Vainio PJ, Smith DJ, Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 2004;103:3388-95
   PubMed Web of Science ®Google Scholar
• Andres N, Lizcano JM, Rodriguez MJ, Tissue activity and cellular localization of human semicarbazide-sensitive amine oxidase. J Histochem Cytochem 2001;49:209-17
   PubMed Web of Science ®Google Scholar
• Ramonet D, Rodriguez M, Saura J, Localization of monoamine oxidase A and B and semicarbazide-sensitive amine oxidase in human peripheral tissues. Inflammopharmacology 2003;11:111-17
   Google Scholar
• Lyles GA. Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. Int J Biochem Cell Biol 1996;28:259-74
   PubMed Web of Science ®Google Scholar
• Massachusetts Eye & Ear Infirmary. Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (VAP-1) inhibitor. WO061830; 2009
   Google Scholar
• Faron Ventures. Method for inhibiting angiogenesis or for treatment of cancer. WO056671; 2009
   Google Scholar
• Noda K, She H, Nakazawa T, Vascular adhesion protein-1 blockade suppresses choroidal neovascularization. FASEB J 2008;22:2928-35
   PubMed Web of Science ®Google Scholar
• Noda K, Miyahara S, Nakazawa T, Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveitis. FASEB J 2008;22:1094-103
   PubMed Web of Science ®Google Scholar
• Almulki L, Noda K, Nakao S, Localization of vascular adhesion protein-1 (VAP-1) in the human eye. Exp Eye Res 2010;90:26-32
   PubMed Web of Science ®Google Scholar
• Forster-Horvath C, Dome B, Paku S, Loss of vascular adhesion-protein-1 expression in intratumoral microvessels of human skin melanoma. Melanoma Res 2004;14:135-40
   Google Scholar
• Marttila-Ichihara F, Auvinen K, Elima K, Vascular adhesion protein-1 enhances tumor growth by supporting recruitment of Gr-1+CD11b+ myeloid cells into tumors. Cancer Res 2009;69:7875-83
   PubMed Web of Science ®Google Scholar
• Marttila-Ichihara F, Castermans K, Auvinen K, Small-molecule inhibitors of vascular adhesion protein-1 reduce the accumulation of myeloid cells into tumors and attenuate tumor growth in mice. J Immunol 2010;184:3164-73
   PubMed Web of Science ®Google Scholar
• Benet Ferrus D, De Borja Corcostegui F, Prieto Garcia JA. Set of antiangiogenic molecules and use thereof. WO138533; 2009
   Google Scholar
• Koskinen K, Nevalainen S, Karikoski M, VAP-1-deficient mice display defects in mucosal immunity and antimicrobial responses: implications for antiadhesive applications. J Immunol 2007;179:6160-8
   Google Scholar
• Stolen CM, Marttila-Ichihara F, Koskinen K, Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 2005;22:105-15
   PubMed Web of Science ®Google Scholar
• Morin N, Lizcano JM, Fontana E, Semicarbazide-sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes. J Pharmacol Exp Ther 2001;297:563-72
   Google Scholar
• Iffiu-Soltesz Z, Wanecq E, Lomba A, Chronic benzylamine administration in the drinking water improves glucose tolerance, reduces body weight gain and circulating cholesterol in high-fat diet-fed mice. Pharmacol Res 2010;61:355-63
   Google Scholar
• Carpene C, Bour S, Visentin V, Amine oxidase substrates for impaired glucose tolerance correction. J Physiol Biochem 2005;61:405-20
   Google Scholar
• Mercader J, Iffiu-Soltesz Z, Brenachot X, SSAO substrates exhibiting insulin-like effects in adipocytes as a promising treatment option for metabolic disorders. Future Med Chem 2010;2:1735-49
   Google Scholar
• Lizcano JM, de Arriba AF, Tipton KF, Unzeta M. Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol 1996;52:187-95
   Web of Science ®Google Scholar
• Nurminen EM, Pihlavisto M, Lazar L, Synthesis, in vitro activity, and three-dimensional quantitative structure-activity relationship of novel hydrazine inhibitors of human vascular adhesion protein-1. J Med Chem 2010;53:6301-15
   PubMed Web of Science ®Google Scholar
• Biotie Therapies Corp. Inhibitors of copper-containing amine oxidases. WO02090; 2002
   Google Scholar
• Biotie Therapies Corp. Crystalline VAP-1 and uses thereof. WO104191; 2004
   Google Scholar
• Biotie Therapies Corp. Hydrazino alcohol derivatives useful as inhibitors of copper-containing amine oxidases. WO080319; 2005
   Google Scholar
• Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases. WO006003; 2003
   Google Scholar
• Marttila-Ichihara F, Smith DJ, Stolen C, Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum 2006;54:2852-62
   PubMed Web of Science ®Google Scholar
• Kiss J, Jalkanen S, Fulop F, Ischemia-reperfusion injury is attenuated in VAP-1-deficient mice and by VAP-1 inhibitors. Eur J Immunol 2008;38:3041-9
   Google Scholar
• Biotie Therapies Corp. Inhibitors of copper-containing amine oxidases. WO02541; 2002
   Google Scholar
• Fulop F, Lazar L, Szakonyi Z, Discovery of new anti-inflammatory agents. Pure Appl Chem 2004;76:965-72
   Google Scholar
• R-Tech Ueno Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor. WO145360; 2009
   Google Scholar
• La Jolla Pharmaceutical Co. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases. WO014530; 2005
   Google Scholar
• La Jolla Pharmaceutical Co. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases. WO094201; 2006
   Google Scholar
• Airas L, Mikkola J, Vainio JM, Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis. J Neuroimmunol 2006;177:132-5
   PubMed Web of Science ®Google Scholar
• O'Rourke AM, Wang EY, Salter-Cid L, Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis. J Neural Transm 2007;114:845-9
   PubMed Web of Science ®Google Scholar
• Castillo V, Lizcano JM, Visa J, Unzeta M. Semicarbazide-sensitive amine oxidase (SSAO) from human and bovine cerebrovascular tissues: biochemical and immunohistological characterization. Neurochem Int 1998;33:415-23
   PubMed Web of Science ®Google Scholar
• Xu H, Salter-Cid L, Linnik MD, Vascular adhesion protein-1 plays an important role in postischemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia. J Pharmacol Exp Ther 2006;317:19-29
   PubMed Web of Science ®Google Scholar
• Jaakkola K, Jalkanen S, Kaunismaki K, Vascular adhesion protein-1, intercellular adhesion molecule-1 and P-selectin mediate leukocyte binding to ischemic heart in humans. J Am Coll Cardiol 2000;36:122-9
   PubMed Web of Science ®Google Scholar
• Wang EY, Gao H, Salter-Cid L, Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase (SSAO) inhibitors with anti-inflammatory activity. J Med Chem 2006;49:2166-73
   PubMed Web of Science ®Google Scholar
• Salter-Cid LM, Wang E, O'Rourke AM, Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase. J Pharmacol Exp Ther 2005;315:553-62
   PubMed Web of Science ®Google Scholar
• Sucampo Ag. Fujisawa Pharmaceutical Co. Ltd. Method for treating vascular hyperpermeable disease. WO087138; 2004
   Google Scholar
• Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and their use as VAP-1 inhibitors. WO067521; 2004
   Google Scholar
• Noda K, Nakao S, Zandi S, Vascular adhesion protein-1 regulates leukocyte transmigration rate in the retina during diabetes. Exp Eye Res 2009;89:774-81
   PubMed Web of Science ®Google Scholar
• Astellas Pharma, Inc. Thiazole derivatives having VAP-1 inhibitory activity. WO011631; 2006
   Google Scholar
• Astellas Pharma, Inc. Thiazole derivatives having VAP-1 inhibitory activity. WO028269; 2006
   Google Scholar
• R-Tech Ueno Ltd. Aqueous composition comprising thiazole derivative. WO089755; 2005
   Google Scholar
• R-Tech Ueno Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor. WO096609; 2009
   Google Scholar
• R-Tech Ueno Ltd. Pharmaceutical composition for treatment of cataract. US0210697; 2010
   Google Scholar
• R-Tech Ueno Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor. WO066145; 2008
   Google Scholar
• R-Tech Ueno Ltd. Composition for ophthalmic disease associated with hypoxia or ischemia. US0190834; 2010
   Google Scholar
• Biovitrum AB. New use of 4,5,6,7-tetrahydroimidazo-[4,5-c]pyridine derivatives. WO38153; 2002
   Google Scholar
• Biovitrum AB. New compounds I. WO031789; 2010
   Google Scholar
• Proximagen Ltd. Imidazopyridine compounds. WO064020; 2010
   Google Scholar
• Biovitrum AB. New compounds II. WO031791; 2010
   Google Scholar
• Merrel Dow Pharmaceuticals, Inc. (E)-2-(p-fluorophenethyl)-3-fluoroallylamine. EP0295604; 1988
   Google Scholar
• Foley P, Gerlach M, Youdim MBH, Riederer P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord 2000;6:25-47
   PubMed Web of Science ®Google Scholar
• La Jolla Pharmaceutical Co. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases. WO120528; 2007
   Google Scholar
• La Jolla Pharmaceutical Co. Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases. WO082343; 2005
   Google Scholar
• Zhang Y, Ran C, Zhou G, Sayre LM. Highly potent 3-pyrroline mechanism-based inhibitors of bovine plasma amine oxidase and mass spectrometric confirmation of cofactor derivatization. Bioorg Med Chem 2007;15:1868-77
   PubMed Web of Science ®Google Scholar
• Lee Y, Ling K, Lu X, 3-Pyrrolines are mechanism-based inactivators of the quinone-dependent amine oxidases but only substrates of the flavin-dependent amine oxidases. J Am Chem Soc 2002;124:12135-43
   PubMed Web of Science ®Google Scholar
• Yu PH, Lu L, Fan H, Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in lipopolysaccharide-induced pulmonary inflammation. Am J Pathol 2006;168:718-26
   PubMed Web of Science ®Google Scholar
• O'Rourke AM, Wang EY, Miller A, Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity. J Pharmacol Exp Ther 2008;324:867-75
   PubMed Web of Science ®Google Scholar
• Pharmaxis Ltd. Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor. WO066152; 2009
   Google Scholar
• La Jolla Pharmaceutical Co. Combined inhibitors of cyclooxygenase and semicarbazide-sensitive amine oxidase (SSAO) (vascular adhesion protein, VAP-1). WO055002; 2009
   Google Scholar
• Genmedica Therapeutics. Compounds for inhibiting copper-containing amine oxidases and uses thereof. WO013209; 2006
   Google Scholar
• Genmedica Therapeutics. Compounds for inhibiting copper-containing amine oxidases and uses thereof. US0066646; 2007
   Google Scholar
• Semmelweis Egyetem. Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/ vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases. WO029379; 2010
   Google Scholar
• O'sullivan J, O'sullivan M, Tipton KF, The inhibition of semicarbazide-sensitive amine oxidase by aminohexoses. Biochim Biophys Acta Proteins Proteomics 2003;1647:367-71
   Google Scholar
• Faron Pharmaceuticals. Aminoglycoside antibiotics for use as VAP-1/SSAO inhibitors. WO063261; 2005
   Google Scholar
• Faron Pharmaceuticals. Compositions useful especially for treatment or prevention of metabolic syndrome. US0206313; 2008
   Google Scholar
• Faron Pharmaceuticals. Compositions useful especially for treatment or prevention of metabolic syndrome. WO025870; 2008
   Google Scholar
• Faron Pharmaceuticals. Compositions for targeting amine oxidases in vivo. WO128951; 2006
   Google Scholar
• Yegutkin GG, Salminen T, Koskinen K, A peptide inhibitor of vascular adhesion protein-1 (VAP-1) blocks leukocyte–endothelium interactions under shear stress. Eur J Immunol 2004;34:2276-85
   Google Scholar
• Faron Ventures. Novel peptides. WO077993; 2008
   Google Scholar
• Kivi E, Elima K, Aalto K, Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate. Blood 2009;114:5385-92
   Google Scholar
• Ujula T, Salomaki S, Virsu P, Synthesis, 68Ga labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: a potential PET imaging agent for diagnosing osteomyelitis. Nucl Med Biol 2009;36:631-41
   Google Scholar
• Lankinen P, Makinen TJ, Poyhonen TA, 68Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones. Eur J Nucl Med Mol Imaging 2008;35:352-64
   Google Scholar
• Silvola J, Autio A, Luoto P, Preliminary evaluation of novel 68Ga-DOTAVAP-PEG-P2 peptide targeting vascular adhesion protein-1. Clin Physiol Funct Imaging 2010;30:75-8
   Google Scholar
• Faron Pharmaceuticals. Compounds for treating or preventing amine oxidase related diseases or disorders. WO134203; 2006
   Google Scholar
• Merinen M, Irjala H, Salmi M, Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am J Pathol 2005;166:793-800
   PubMed Web of Science ®Google Scholar
• Biotie Therapies Corp. Novel humanized anti-VAP-1 monoclonal antibody. WO093319; 2003
   Google Scholar
• Kirton CM, Laukkanen M, Nieminen A, Function-blocking antibodies to human vascular adhesion protein-1: A potential anti-inflammatory therapy. Eur J Immunol 2005;35:3119-30
   PubMed Web of Science ®Google Scholar
• Biotie Therapies Corp. Novel fully human anti-VAP-1 monoclonal antibodies. WO129124; 2008
   Google Scholar
• Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis. Basic Clin Pharmacol Toxicol 2005;96:429-35
   PubMed Web of Science ®Google Scholar
• Bono P, Jalkanen S, Salmi M. Mouse vascular adhesion protein 1 is a sialoglycoprotein with enzymatic activity and is induced in diabetic insulitis. Am J Pathol 1999;155:1613-24
   Google Scholar
• Salmi M, Stolen C, Jousilahti P, Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am J Pathol 2002;161:2255-62
   PubMed Web of Science ®Google Scholar
• Li H, Lin M, Wei J, Change of serum vascular adhesion protein-1 after glucose loading correlates to carotid intima-medial thickness in non-diabetic subjects. Clin Chim Acta 2009;403:97-101
   PubMed Web of Science ®Google Scholar
• Li H, Wei J, Lin M, Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia. Clin Chim Acta 2009;404:149-53
   PubMed Web of Science ®Google Scholar
• Visentin V, Bour S, Boucher J, Glucose handling in streptozotocin-induced diabetic rats is improved by tyramine but not by the amine oxidase inhibitor semicarbazide. Eur J Pharmacol 2005;522:139-46
   Google Scholar
• Yu PH, Wang M, Fan H, Involvement of SSAO-mediated deamination in adipose glucose transport and weight gain in obese diabetic KKAy mice. Am J Physiol Endocrinol Metab 2004;286:E634-41
   Google Scholar
• Roessner V, Weber A, Becker A, Decreased serum activity of semicarbazide-sensitive amine oxidase (SSAO) in patients treated with second generation antipsychotics: a link to impaired glucose metabolism? Eur J Clin Pharmacol 2007;63:425-9
   Google Scholar
• Stolen CM, Madanat R, Marti L, Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. FASEB J 2004;18:702-4
   PubMed Web of Science ®Google Scholar
• Marti L, Abella A, de la Cruz X, Exploring the binding mode of semicarbazide-sensitive amine oxidase/VAP-1: identification of novel substrates with insulin-like activity. J Med Chem 2004;47:4865-74
   Google Scholar
• Yraola F, Garcia-Vicente S, Fernandez-Recio J, New efficient substrates for semicarbazide-sensitive amine oxidase/VAP-1 enzyme: analysis by SARs and computational docking. J Med Chem 2006;49:6197-208
   PubMed Web of Science ®Google Scholar
• Bonaiuto E, Lunelli M, Scarpa M, A structure-activity study to identify novel and efficient substrates of the human semicarbazide–sensitive amine oxidase/VAP1 enzyme. Biochimie 2010;92:858-68
   PubMed Web of Science ®Google Scholar
• Universidad de Barcelona. Combination of amines and vanadium(IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus. WO38152; 2002
   Google Scholar
• Genmedica Therapeutics. Compositions of SSAO substrates and metal compounds of the VIA and VIB groups of the periodic table. WO061140; 2006
   Google Scholar
• Genmedica Therapeutics. Meta-xylylenediamine vanadate salts. WO131996; 2007
   Google Scholar
• Yraola F, Garcia-Vicente S, Marti L, Understanding the mechanism of action of the novel SSAO substrate (C7NH10)6(V10O28)·2H2O, a prodrug of peroxovanadate insulin mimetics. Chem Biol Drug Des 2007;69:423-8
   Google Scholar
• Zorzano A, Palacin M, Marti L, Garcia-Vicente S. Arylalkylamine vanadium salts as new anti-diabetic compounds. J Inorg Biochem 2009;103:559-66
   Google Scholar
• VAP-1 antibody product profile. Biotie 2011. Available from: http://www.biotie.com/en/recearch_and_development/inflammation/vap1_antibody [Last accessed April 2011]
   Google Scholar
• Lewinsohn R. Human serum amine oxidase. Enzyme activity in severely burnt patients and in patients with cancer. Clin Chim Acta 1977;81:247-56
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Miki C, Inoue Y, Circulating form of human vascular adhesion protein-1 (VAP-1): decreased serum levels in progression of colorectal cancer and predictive marker of lymphatic and hepatic metastasis. J Surg Oncol 2009;99:368-72
   PubMed Web of Science ®Google Scholar
• Garpenstrand H, Bergqvist M, Brattstrom D, Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients. Med Oncol 2004;21:241-50
   PubMed Web of Science ®Google Scholar
• Ekblom J, Gronvall J, Lennernast B, Elevated activity of semicarbazide-sensitive amine oxidase in blood from patients with skeletal metastases of prostate cancer. Clin Sci 1999;97:111-15
   PubMed Web of Science ®Google Scholar
• Irjala H, Salmi M, Alanen K, Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium. J Immunol 2001;166:6937-43
   PubMed Web of Science ®Google Scholar
• Maula S, Luukkaa M, Grenman R, Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003;63:1920-6
   PubMed Web of Science ®Google Scholar
• Enzsoly A, Dunkel P, Recsan Z, Preliminary studies of the effects of vascular adhesion protein-1 inhibitors on experimental corneal neovascularization. J Neural Transm 2011; DOI:10.1007/s00702-011-0595-8
   Google Scholar
• Boomsma F, van Veldhuisen DJ, de Kam PJ, Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res 1997;33:387-91
   PubMed Web of Science ®Google Scholar
• Boomsma F, De Kam PJ, Tjeerdsma G, Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Eur Heart J 2000;21:1859-63
   PubMed Web of Science ®Google Scholar
• Olive M, Unzeta M, Moreno D, Ferrer I. Overexpression of semicarbazide-sensitive amine oxidase in human myopathies. Muscle Nerve 2004;29:261-6
   Google Scholar
• Boomsma F, van den Meiracker AH, Winkel S, Circulating semicarbazide-sensitive amine oxidase is raised both in Type I (insulin-dependent), in Type II (non-insulin-dependent) diabetes mellitus and even in childhood Type I diabetes at first clinical diagnosis. Diabetologia 1999;42:233-7
   PubMed Web of Science ®Google Scholar
• Boomsma F, Pedersen-Bjergaard U, Agerholm-Larsen B, Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus. Diabetologia 2005;48:1002-7
   PubMed Web of Science ®Google Scholar
• Meszaros Z, Szombathy T, Raimondi L, Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride. Metabolism 1999;48:113-17
   Google Scholar
• Karadi I, Meszaros Z, Csanyi A, Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis. Clin Chim Acta 2002;323:139-46
   PubMed Web of Science ®Google Scholar
• Nunes SF, Figueiredo IV, Soares PJ, Semicarbazide-sensitive amine oxidase activity and total nitrite and nitrate concentrations in serum: novel biochemical markers for type 2 diabetes? Acta Diabetol 2009;46:135-40
   PubMed Web of Science ®Google Scholar
• Nunes SF, Figueiredo IV, Pereira JS. Changes in the activities of semicarbazide-sensitive amine oxidase in inferior mesenteric artery segments and in serum of patients with type 2 diabetes. Acta Diabetol 2010;47:179-82
   Google Scholar
• Gronvall-Nordquist JLE, Backlund LB, Garpenstrand H, Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus. J Diabetes Complications 2001;15:250-6
   PubMed Web of Science ®Google Scholar
• Garpenstrand H, Ekblom J, Backlund LB, Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy. Diabetic Med 1999;16:514-21
   PubMed Web of Science ®Google Scholar
• Weiss HG, Klocker J, Labeck B, Plasma amine oxidase: a postulated cardiovascular risk factor in nondiabetic obese patients. Metabolism 2003;52:688-92
   PubMed Web of Science ®Google Scholar
• Dullaart RPF, Riemens SC, Boomsma F. Plasma semicarbazide-sensitive amine oxidase is moderately decreased by pronounced exogenous hyperinsulinemia but is not associated with insulin sensitivity and body fat. Scand J Clin Lab Invest 2006;66:559-66
   Web of Science ®Google Scholar
• Visentin V, Prevot D, De Saint Front VD, Alteration of amine oxidase activity in the adipose tissue of obese subjects. Obes Res 2004;12:547-55
   Google Scholar
• Madej A, Reich A, Orda A, Szepietowski JC. Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. J Eur Acad Dermatol Venereol 2007;21:72-8
   PubMed Web of Science ®Google Scholar
• Madej A, Reich A, Orda A, Szepietowski JC. Expression of vascular adhesion protein-1 in atopic eczema. Int Arch Allergy Immunol 2006;139:114-21
   Google Scholar
• Ferrera I, Lizcano JM, Hernandez M, Unzeta M. Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett 2002;321:21-4
   Google Scholar
• Jiang ZJ, Richardson JS, Yu PH. The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathol Appl Neurobiol 2008;34:194-204
   PubMed Web of Science ®Google Scholar
• Unzeta M, Sole M, Boada M, Hernandez M. Semicarbazide-sensitive amine oxidase (SSAO) and its possible contribution to vascular damage in Alzheimer's disease. J Neural Transm 2007;114:857-62
   PubMed Web of Science ®Google Scholar
• del Mar Hernandez M, Esteban M, Szabo P, Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging. Neurosci Lett 2005;384:183-7
   PubMed Web of Science ®Google Scholar
• Nemcsik J, Szoko e, Soltesz Z, Alteration of serum semicarbazide-sensitive amine oxidase activity in chronic renal failure. J Neural Transm 2007;114:841-3
   PubMed Web of Science ®Google Scholar
• Lin M, Li H, Wei J, Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. Clin Biochem 2008;41:1362-7
   PubMed Web of Science ®Google Scholar
• Kurkijarvi R, Jalkanen S, Isoniemi H, Salmi M. Vascular adhesion protein-1 (VAP-1) mediates lymphocyte-endothelial interactions in chronic kidney rejection. Eur J Immunol 2001;31:2876-84
   Google Scholar
• Kurkijarvi R, Adams DH, Leino R, Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol 1998;161:1549-57
   PubMed Web of Science ®Google Scholar
• Kurkijarvi R, Yegutkin GG, Gunson BK, Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology 2000;119:1096-103
   PubMed Web of Science ®Google Scholar
• Airas L, Lindsberg PJ, Karjalainen-Lindsberg M, Vascular adhesion protein-1 in human ischaemic stroke. Neuropathol Appl Neurobiol 2008;34:394-402
   Google Scholar